RIGEL PHARMACEUTICALS,INC. (NASDAQ:RIGL) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March22, 2019, Jane Wasman, J.D., was appointed to serve on Rigel’s Board, until her successor is elected and has qualified, or sooner in the event of her death, resignation or removal. Ms.Wasman joins the class of directors whose term expires at the 2019 annual stockholders’ meeting.

As a non-employee director of Rigel, Ms.Wasman will receive a yearly retainer of $50,000.

In addition to the cash compensation referenced in the preceding paragraph, Ms.Wasman will receive stock option grants under Rigel’s 2018 Equity Incentive Plan, or the 2018 Plan. Option grants under the 2018 Plan are non-discretionary. Upon the date of her appointment, Ms.Wasman received an initial grant to purchase 80,000 shares of common stock on the terms and conditions set forth in the 2018 Plan. In addition, on the day following each annual meeting of stockholders, Ms.Wasman will automatically receive an annual option to purchase 55,000 shares of common stock, prorated to 25% for each full quarter of the prior year she was a member of the Board, provided that she continues to serve as a non-employee member of Rigel’s Board. Rigel has also entered into its standard form of indemnification agreement with Ms.Wasman.

There are no arrangements or understandings between Ms.Wasman and any other persons to which she was elected as a member of Rigel’s Board. There are no family relationships between Ms.Wasman and any director, executive officer, or any person nominated or chosen by Rigel to become a director or executive officer. Ms.Wasman is not a party to any current or proposed transaction with Rigel for which disclosure is required under Item 404(a)of Regulation S-K.